H-Ala-Gly-Cys(1)-Lys-Asn-Phe-Phe-Trp-DL-Lys-Thr-Phe-Thr-Ser-Cys(1)-OH

• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 英文名称: H-Ala-Gly-Cys(1)-Lys-Asn-Phe-Phe-Trp-DL-Lys-Thr-Phe-Thr-Ser-Cys(1)-OH
• 英文别名: (4R,7S,10S,13S,16S,22S,25S,28S,31S,34S,37R)-19,34-bis(4-aminobutyl)-31-(2-amino-2-oxoethyl)-37-[[2-[[(2S)-2-aminopropanoyl]amino]acetyl]amino]-13,25,28-tribenzyl-10,16-bis[(1R)-1-hydroxyethyl]-7-(hydroxymethyl)-22-(1H-indol-3-ylmethyl)-6,9,12,15,18,21,24,27,30,33,36-undecaoxo-1,2-dithia-5,8,11,14,17,20,23,26,29,32,35-undecazacyclooctatriacontane-4-carboxylic acid
• 化学式: C₇₆H₁₀₄N₁₈O₁₉S₂
• 分子量: 1637.9
• InChiKey: NHXLMOGPVYXJNR-PWRXAIMWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  115
• 可旋转键数：
  26
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  664
• 氢给体数：
  22
• 氢受体数：
  24

文献信息

• METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY (BPH)
  申请人：Kleinberg David L.

  公开号：US20140349937A1

  公开（公告）日：2014-11-27

  Therapeutic methods for treating a subject with benign prostatic hypertrophy by inhibition of the activity of insulin-like growth factor-I (IGF-I) to reduce the amount of prostatic hyperplastic tissue in the subject are described herein.
• METHODS FOR DETECTING PROGENITOR CELLS AND USES THEREOF
  申请人：Kleinberg David L.

  公开号：US20150099700A1

  公开（公告）日：2015-04-09

  Diagnostic and therapeutic methods pertaining to diseases and disorders of the breast, uterus and ovary are encompassed herein. More particularly, diagnostic methods for early detection of progenitor cells of breast, uterine, and ovarian cancers are described herein. The identification of markers for these cancer predisposing progenitor cells, which co-express the progesterone receptor (PR) and p63, provides tools and methods of use thereof that facilitate early detection of increased frequency of PR/p63 double positive (PR/p63+) progenitor cells in asymptomatic patients and thus, early detection of increased cancer risk in such patients and assessment, diagnostic stratification, and evaluation of therapeutic intervention in symptomatic patients. Therapeutic methods are also encompassed herein, which include detection of PR/p63+ progenitor cells in a patient, wherein detection of increased frequency of PR/p63+ progenitor cells provides information on which basis a determination of therapeutic regimen or an assessment of an ongoing therapeutic regimen can be made.
• US8835123B2
  申请人：——

  公开号：US8835123B2

  公开（公告）日：2014-09-16
• US9408887B2
  申请人：——

  公开号：US9408887B2

  公开（公告）日：2016-08-09
• US9579364B2
  申请人：——

  公开号：US9579364B2

  公开（公告）日：2017-02-28